SYNBIOTIC presents medical cannabis as a pastille for the German market for the first time
|
EQS-News: SYNBIOTIC SE
/ Key word(s): Product Launch
SYNBIOTIC presents medical cannabis as a pastille for the German market for the first time
SYNBIOTIC SE (ISIN DE000A3E5A59 | WKN A3E5A5), the European group of companies specialising in medical cannabis and industrial hemp, is launching medical cannabis pastilles on the German market for the first time during the second quarter. The pastille formulation was developed over three years in collaboration with BOLDER Arzneimittel GmbH & Co KG and experienced partner pharmacies. This innovative form of application makes it possible to administer cannabinoids in the way that patients and healthcare professionals expect: customised to the patient, fast and therapeutically effective, pleasant in taste, very well tolerated - and free from social stigma. To date, medical cannabis has mainly been available in German pharmacies in the form of dried flowers or extracts. "The currently available dosage forms for medical cannabis all have their major or minor disadvantages. Our goal with the pastille was to develop a dosage form with the most advantages and now we have succeeded.", says Daniel Kruse, Managing Director of SYNBIOTIC. "This personalised medicine will set new standards for the administration of cannabis-based medicines and make cannabis therapy much easier and safer for many patients." The cannabis pastilles from SYNBIOTIC are particularly convincing due to their pharmaceutical-technological advantages, such as fast and uncomplicated processing in the pharmacy and the exact and reproducible dosing of THC in combination with simple and discreet application for patients. Where there's a will, there is a pastille Medical cannabis has been permitted in Germany since 10 March 2017. However, even after eight years, the available dosage forms are more than limited and offer hardly any therapeutic scope. New medical forms have mostly failed due to legal and billing-related framework conditions as well as practical production in pharmacies as prescription drugs. The THC-containing pastille is a patient-individualised form of application. It consists of pharmacy-known, pharmaceutically certified excipients and the medically prescribed amount of cannabis active ingredient. It protects the enclosed cannabinoids until the patient-specific application. WEECO Pharma GmbH and MH medical hemp GmbH, both subsidiaries of SYNBIOTIC, supply all partner pharmacies with the components on behalf of SYNBIOTIC. The cannabis pastilles can only be prescribed by the treating doctor on a patient-specific basis and produced in the pharmacy according to the prescription issued. "We at WEECO Pharma are absolutely convinced by this innovative product. The expansion of the product range comes at the perfect time and we look forward to working closely with our pharmacy network," says Börge Diessel, Managing Director of WEECO Pharma. About BOLDER BOLDER Arzneimittel GmbH & Co KG is the market leader for the development and contract manufacturing of pharmaceutical and specialises exclusively in this dosage form. The Cologne-based company has more than 100 years of expertise in the manufacture of pharmaceuticals and produces well over a billion every year. BOLDER allow the processing of different active ingredients - whether as a solution, emulsion or suspension. This makes pastilles an optimal dosage form for many indications. Website www.bolder.de Publisher SYNBIOTIC SE Daniel Kruse Managing Director Münsterstrasse 336 40470 Düsseldorf Germany www.synbiotic.com Media contact Rüdiger Tillmann SYNBIOTIC Public Relations Manager e-mail ruediger.tillmann@synbiotic.com Mobile +49 170 9651451 c/o JOLE.group About SYNBIOTIC SYNBIOTIC is a listed group of companies in the medical cannabis and industrial hemp sector with a buy-and-build investment strategy focussed on Europe. The Group covers the entire value chain from cultivation to production and retail - from the field to the shelf. The subsidiaries' core businesses are research and development, production and the commercialisation of medical cannabis, industrial hemp and CBD products. SYNBIOTIC is pursuing a clear pan-European strategy of further expanding its business areas in order to cover the relevant growth markets while minimising risks and increasing opportunities for investors through diversification.
01.04.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
| Language: | English |
| Company: | SYNBIOTIC SE |
| Münsterstr. 336 | |
| 40470 Dusseldorf | |
| Germany | |
| E-mail: | office@synbiotic.com |
| Internet: | https://www.synbiotic.com/ |
| ISIN: | DE000A3E5A59 |
| WKN: | A3E5A5 |
| Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt, Munich, Tradegate Exchange |
| EQS News ID: | 2109988 |
| End of News | EQS News Service |
|
|
2109988 01.04.2025 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.